Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

Blood. 2009 May 7;113(19):4819-20. doi: 10.1182/blood-2009-02-207209.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / drug therapy*
  • Prognosis
  • Pyrimidines / therapeutic use*
  • Safety
  • Salvage Therapy*
  • Sulfonamides / therapeutic use*
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Pyrimidines
  • Sulfonamides
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • pazopanib